Compare CBLL & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBLL | HELP |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 935.3M | 862.2M |
| IPO Year | 2024 | 2020 |
| Metric | CBLL | HELP |
|---|---|---|
| Price | $27.56 | $9.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $31.57 | ★ $41.56 |
| AVG Volume (30 Days) | 647.2K | ★ 1.5M |
| Earning Date | 11-03-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $89,063,000.00 | N/A |
| Revenue This Year | $29.72 | N/A |
| Revenue Next Year | $27.43 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.09 | N/A |
| 52 Week Low | $11.75 | $3.76 |
| 52 Week High | $28.89 | $15.15 |
| Indicator | CBLL | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 41.61 |
| Support Level | $22.96 | $4.41 |
| Resistance Level | $28.11 | $11.74 |
| Average True Range (ATR) | 1.67 | 0.90 |
| MACD | -0.11 | -0.10 |
| Stochastic Oscillator | 81.38 | 33.53 |
CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.